1060816-67-2

Usage

Uses

Used in Pharmaceutical Industry:
2-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine is used as a building block for the synthesis of pharmaceuticals, leveraging its structural properties to create new drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine is employed as a key component in the development of new agrochemicals, contributing to the creation of innovative products for agricultural use.
Used in Organic Chemistry Research:
As a versatile reagent, 2-Chloro-7-methyl-7H-pyrrolo[2,3-d]pyrimidine is utilized in organic chemistry for the preparation of a variety of functionalized pyrrolopyrimidines and related analogs, facilitating the exploration of new chemical reactions and the synthesis of novel compounds.

InChI:InChI=1S/C7H6ClN3/c1-11-3-2-5-4-9-7(8)10-6(5)11/h2-4H,1H3

Upstream product

• 335654-06-3 2-chloro-7H-pyrrolo[2,3-d]pyrimidine 
• 74-88-4 methyl iodide 

Relevant academic research and scientific papers

Diversification of Heteroaryl-Aryl Ether via Ligand-Free, Copper-Catalyzed O-Arylation Under Microwave Heating

Diverse O-arylated pyrrolo[2,3-d]pyrimidine and pyrrolo[2,3-b]pyridine were obtained using relatively low amounts of Cu catalyst with ligand-free conditions under microwave heating. The O-arylation reaction could be applied to less oxidative heteroaryl-chlorides. The microwave-assisted Cu-catalyzed O-aryaltion would be useful for preparing potent bioactive compounds for drug discovery while reducing waste, time, and saving energy.

FUSED-BICYCLIC ARYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS

The invention relates to inhibitors of mutant isocitrate dehydrogenase (mt-IDH) proteins with neomorphic activity useful in the treatment of cell-proliferation disorders and cancers, having the Formula (I) where A, B, U, V, Z, W1, W2, W3, and R1-R6 are described herein.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described

N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS

The present invention relates to N-(hetero)aryl-pyrrolidine derivatives of Formula I: which are JAK inhibitors, such as selective JAK1 inhibitors, useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.